mRNA translation is thought to be the most energyconsuming process in the cell. Translation and energy metabolism are dysregulated in a variety of diseases including cancer, diabetes, and heart disease. However, the mechanisms that coordinate translation and energy metabolism in mammals remain largely unknown. The mechanistic/mammalian target of rapamycin complex 1 (mTORC1) stimulates mRNA translation and other anabolic processes. We demonstrate that mTORC1 controls mitochondrial activity and biogenesis by selectively promoting translation of nucleus-encoded mitochondria-related mRNAs via inhibition of the eukaryotic translation initiation factor 4E (eIF4E)-binding proteins (4E-BPs). Stimulating the translation of nucleus-encoded mitochondria-related mRNAs engenders an increase in ATP production capacity, a required energy source for translation. These findings establish a feed-forward loop that links mRNA translation to oxidative phosphorylation, thereby providing a key mechanism linking aberrant mTOR signaling to conditions of abnormal cellular energy metabolism such as neoplasia and insulin resistance.
INTRODUCTION
Translation is considered to be one of the most energyconsuming cellular processes, accounting for $20%-30% of total ATP consumption, not including the energy expended during the biosynthesis of rRNA (Buttgereit and Brand, 1995; Rolfe and Brown, 1997) . Mitochondria are the main producers of ATP under physiological conditions in mammals and play a critical role in overall energy balance (Vander Heiden et al., 2009) .
The mechanistic/mammalian target of rapamycin (mTOR) is a serine/threonine kinase that has been implicated in a variety of physiological processes and pathological states (Zoncu et al., 2011) . mTOR forms two distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), which differ in their composition, downstream targets, regulation, and sensitivity to the allosteric inhibitor rapamycin (Hara et al., 2002; Kim et al., 2002; Sarbassov et al., 2004) . mTORC1 stimulates mRNA translation and other anabolic processes (e.g., lipogenesis) in response to a variety of extracellular signals and intracellular cues such as nutrients, oxygen, and hormones (Laplante and Sabatini, 2012; Yecies and Manning, 2011) . mTORC2 controls cell survival, cytoskeleton organization (Jacinto et al., 2004; Sarbassov et al., 2004) , lipogenesis, and gluconeogenesis (Hagiwara et al., 2012; Yuan et al., 2012) by activating AGC kinases including serum-and glucocorticoid-regulated kinase (SGK) and AKT (García-Martínez and Alessi, 2008; Ikenoue et al., 2008; Sarbassov et al., 2005) . Hyperactivation of mTORC1 frequently accompanies diseases characterized by perturbations in energy metabolism and translation including cancer and the metabolic syndrome (Laplante and Sabatini, 2012) . mTORC1 stimulates translation by phosphorylating downstream targets including 4E-BPs and ribosomal protein S6 kinases (S6Ks) (Roux and Topisirovic, 2012) . Phosphorylation of 4E-BPs by mTORC1 leads to their dissociation from eIF4E, thereby allowing association of eIF4E with eIF4G and the assembly of the eIF4F translation initiation complex at the mRNA 5 0 end (Gingras et al., 1999 (Gingras et al., , 2001 Pause et al., 1994) . S6Ks phosphorylate components of the translational machinery and associated factors such as ribosomal protein S6, eIF4B, and PDCD4 (Banerjee et al., 1990; Dorrello et al., 2006; Kozma et al., 1990; Shahbazian et al., 2006) . mTORC1 also controls energy metabolism by stimulating the activity of several transcriptional regulators such as PPARg coactivator-1a (PGC-1a), sterol regulatory element-binding protein 1/2 (SREBP1/2), and hypoxia inducible factor-1a (HIF-1a) (Cunningham et al., 2007; Dü vel et al., 2010; Porstmann et al., 2008) . Therefore, mTORC1 is thought to be an integral node in a network that couples cellular energy production to consumption.
In this study, we demonstrate that mTORC1 stimulates mitochondrial biogenesis and activity, thereby bolstering ATP production capacity. mTOR inhibitors caused a decrease in ATP levels associated with impaired mitochondrial function and glycolysis. At the molecular level, this is explained by preferential inhibition of translation of a subset of cellular mRNAs that encode for essential nucleus-encoded mitochondrial proteins including the components of complex V and TFAM (transcription factor a, mitochondrial). Moreover, we show that 4E-BPs mediate the stimulatory effect of mTORC1 on the translation of mitochondria-related mRNAs, mitochondrial respiration and biogenesis, and ATP production in vitro and in vivo. These data reveal a feed-forward mechanism by which translation impacts mitochondrial function to maintain energy homeostasis in the cell.
RESULTS mTOR Regulates Translation of a Subset of Mitochondria-Related mRNAs
We recently identified mRNAs whose translation was affected by mTOR inhibitors (Larsson et al., 2012) using genomewide polysome profiling (Larsson et al., , 2011 . Among the mRNAs whose translation was suppressed after 12 hr treatment with the active-site mTOR inhibitor (asTORi) PP242, those encoding mitochondria-related proteins were highly abundant (14% of target mRNAs) (Table S1 ). Indeed, pathway analysis using the generally applicable gene-set enrichment (GAGE) method (Luo et al., 2009 ) revealed a significant enrichment of genes annotated to mitochondria-related functions as translationally suppressed by PP242 ( Figure 1A ). mRNAs encoding components of complex V (ATP synthase) in the oxidative phosphorylation pathway were the most significantly enriched (Figure 1A) and included ATP synthase subunit delta (ATP5D), ATP5G1, ATP5L, and ATP5O ( Figure 1B ) (Hoffmann et al., 2010) . mRNAs encoding TFAM (transcription factor A, mitochondrial), which promotes mitochondrial DNA replication and transcription (Bonawitz et al., 2006) , mitochondrial ribosomal proteins, and NADH dehydrogenase 1 alpha subcomplex assembly factors 2 and 4 (NDUFAF2 and 4), were also significantly enriched (Figures 1A and 1B) . mTOR also regulates transcription of mitochondrial genes via PGC-1a (Blä ttler et al., 2012; Cunningham et al., 2007) . Potential effects of mTOR inhibition on mitochondrial function that are caused by transcriptional mechanisms could therefore obscure those that occur at the level of translation. To exclude this possibility, we compared the effects of PP242 on transcriptional and translational activity, which revealed that after 12 hr treatment PP242 strongly inhibited translation of a subset of mitochondria-related mRNAs, while having only a marginal effect on transcription of the corresponding genes ( Figure 1C ). Consistently, the assessment of mitochondrial functions upon ectopic expression of the transcriptional coactivators (e.g., PGC-1a) has typically been performed after 48 hr or longer (Lehman et al., 2000; St-Pierre et al., 2003) . Thus, 12 hr asTORi treatment is adequate to determine the effects of translation on mitochondrial activity, without substantial interference from transcriptional mechanisms.
We next validated the effect of two asTORi: Ink1341 (derived from the PP242 chemical scaffold ) and Torin1 (Thoreen et al., 2009 ) on the translation of several mitochondriarelated mRNAs in MCF7 cells using polysome profiling. As reported previously (Thoreen et al., 2009; Yu et al., 2009) , the phosphorylation of 4E-BP1, 4E-BP2, and ribosomal protein S6 was abolished by asTORi ( Figure 2A ). Accordingly, asTORi strongly impaired the eIF4F complex assembly as monitored by a cap pull-down assay ( Figure 2B ). To directly investigate whether asTORi suppress translation of mitochondria-related mRNAs, polysomes from MCF7 cells treated with asTORi were sedimented in sucrose density gradients to separate efficiently translated mRNAs (associated with heavy polysomes) from those that are poorly translated (associated with light polysomes) ( Figure 2C ). asTORi inhibited protein synthesis, as illustrated by the decrease in polysome content with a concomitant increase in the 80S peak ( Figure 2C ). Consistent with previous findings Hsieh et al., 2012; Thoreen et al., 2012) , Ink1341 and Torin1 did not induce complete disassembly of polysomes ( Figure 2C ), indicating that these compounds selectively block translation of a subset of mRNAs. Indeed, 12 hr Torin1 treatment caused a $35% decrease in global translation relative to a control as measured by [ 35 S]methionine/ cysteine labeling ( Figure S1 ). Thus, we assessed the effects of Ink1341 and Torin1 on polysomal distribution of ATP5O, ATP5D, and TFAM mRNAs, which were identified as mTORsensitive ( Figure 1B) , and b-actin mRNA, which is resistant to mTOR inhibitors (Hsieh et al., 2012; Larsson et al., 2012) . asTORi suppressed translation of ATP5D, ATP5O, and TFAM mRNAs, as illustrated by a shift of these mRNAs toward lighter polysomes ( Figure 2D ), whereas asTORi failed to shift the b-actin mRNA ( Figure 2D ). Consistently, ATP5O, ATP5D, and TFAM but not b-actin protein levels were decreased in asTORi-treated cells (Figure 2A ). In contrast to ATP5O, ATP5D, and TFAM, expression of COX4I1 protein that is a component of oxidative phosphorylation complex IV (Fornuskova et al., 2010) was not sensitive to asTORi (Figure 2A ). These data indicate that mTOR controls translation of a subset of, but not all, mitochondriarelated mRNAs.
mTOR Controls Mitochondrial Function and ATP Production
Since asTORi inhibited translation of ATP5D, ATP5O, and TFAM mRNAs, we wished to investigate the effects of asTORi on mitochondrial activity. MCF7 cells were treated with a vehicle, PP242 or Ink1341, for 12 hr, and the rate of mitochondrial respiration was determined using a Clark-type electrode ( Figures 3A-3D ). asTORi decreased total mitochondrial respiration ($35%) as compared to vehicle control ( Figure 3A ). There are two types of mitochondrial respiration: coupled respiration (drives oxidative phosphorylation and ATP synthesis) and uncoupled respiration (represents proton leak reactions) (Rolfe and Brown, 1997) . asTORi decreased both coupled ($30%) and uncoupled respiration ($40%) ( Figures 3B and 3C ). The fraction of cellular respiration dedicated to coupling and uncoupling remained constant between asTORi-and vehicle-treated cells ( Figure 3D ). Similar S2D ), thus indicating that the effects of asTORi on respiration are not limited to malignant cells. Therefore, asTORi exert a general effect on cellular energy production by suppressing respiration in proliferating cells.
Since our data showed that asTORi inhibited mRNA translation and mitochondrial respiration, we asked whether asTORi also change the steady-state levels of metabolites involved in major bioenergetic pathways. Intracellular metabolite levels in MCF7 cells were measured using gas chromatography-mass spectrometry (GC-MS) and 1 H nuclear magnetic resonance (NMR) spectroscopy. Ink1341 and PP242 strongly reduced tricarboxylic acid (TCA) cycle intermediates as compared to control ( Figures 3E and S2E ). This striking decrease in TCA cycle intermediates, in conjunction with diminished respiration, indicates reduced mitochondrial functions. asTORi also induced intracellular accumulation of glucose (58%) and decreased lactate and pyruvate (51% and 45%, respectively Figure S1 . and S2G), which is consistent with the stimulatory role of mTOR in glycolysis (Dü vel et al., 2010; Hagiwara et al., 2012; Yuan et al., 2012) . To investigate the effects of asTORi on carbon flux through glycolysis and the TCA cycle, we cultured cells in a medium containing the uniformly labeled D[U-13 C]glucose for 30 min and measured 13 C enrichment of intracellular metabolites by GC-MS (Figures 3F, S2H, and S2I) (Nanchen et al., 2007) . In the cytosol, D[U-13 C] glucose through glycolysis produces pyruvate m+3 (pyruvate mass shift by three units from 13 C), which is translocated to the mitochondria or metabolized to lactate m+3 ( Figure S2H ). In the mitochondria, pyruvate m+3 is converted to acetyl-CoA (coenzyme A) m+2, which enters the TCA cycle to produce citrate m+2 upon reaction with oxaloacetate ( Figure S2H ). Processing of citrate m+2 in the second round of the TCA cycle produces citrate m+4 ( Figure S2H ). In vehicle-treated cells, most citrate molecules contained glucose-derived 13 C ( Figure 3F , upper). In Ink1341-treated cells, the proportion of citrate m+4 was dramatically decreased, and the one citrate m+2 was also decreased, while the one unlabeled citrate (m+0) was increased ( Figure 3F , upper). The proportion of isocitrate m+2 and m+4 as well as a-ketoglutarate m+2 and m+4 were also diminished in Ink1341-treated cells ( Figure 3F , lower). Furthermore, Ink1341 increased the proportion of unlabeled pyruvate and lactate (m+0) ( Figure S2I ). These data show that mTOR activity regulates the flux of glucose through TCA cycle and glycolysis. In addition, asTORi treatment decreased mitochondrial DNA content and mitochondrial mass ( Figures 3G-3I ). Finally, cellular ATP (B) A subset of mRNAs encoding mitochondrial proteins that are translationally suppressed following 12 hr treatment with PP242 (FDR < 0.05; percentage decrease relative to control is indicated). (C) Kernel density plot shows a comparison of fold changes (PP242 versus vehicle treatment) in the upstream mechanisms of regulation of gene expression (e.g., transcription) that are reflected in steady-state mRNA levels (blue line) or translation (black line) for the subset of genes described in Table S1 . Stronger shift of ''translation'' curve toward ordinate compared to that observed for steady-state mRNA levels indicates that after 12 hr of PP242 treatment, downregulation of genes described in Table S1 occurs mostly at the translational level, whereas the contribution of the upstream mechanisms of regulation of gene expression (e.g., transcription) is minimal. See also Table S1 .
Cell Metabolism mTORC1/4E-BP Controls Mitochondrial Function concentration was measured by liquid chromatography-mass spectrometry (LC-MS). Consistent with the downregulation of mitochondrial functions and glycolysis, a significant decrease ($30%) in the ATP pool was observed in asTORi-treated cells as compared to control ( Figure 3J ). These findings imply that the inhibition of mitochondria-associated mRNA translation by asTORi results in downregulation of TCA cycle activity and ATP production capacity. To determine which mTOR complex is a major regulator of mitochondrial function, MCF7 cells were depleted of raptor or rictor, which are specific components of mTORC1 and mTORC2, respectively ( Figure 4A ). Raptor depletion decreased the phosphorylation of S6K, 4E-BP1, and 4E-BP2, while rictor knockdown reduced the phosphorylation of Akt ( Figure 4A ) (Sarbassov et al., 2005) . Depletion of raptor, but not rictor, caused a decrease in ATP5O and TFAM proteins ( Figure 4A ). Depletion of raptor was paralleled by the reduction in mitochondrial respiration (Figures Hagiwara et al., 2012; Schieke et al., 2006; Yuan et al., 2012) . Interestingly, depletion of rictor also decreased the amount of a-ketoglutarate ( Figure 4F ). In MCF7 cells, the majority of a-ketoglutarate ($70%) was unlabelled ( Figure 3F ). This suggests that in MCF7 cells, a-ketoglutarate is derived from other metabolic pathways such as glutaminolysis (Ward and Thompson, 2012) , thereby suggesting that mTORC2 may regulate this process. In addition, raptor knockdown diminished intracellular ATP levels and mtDNA content relative to control, whereas depletion of rictor had no effect ( Figures 4G and 4H) . These findings indicate that the effects of mTOR signaling on mitochondrial biogenesis and functions are mostly mediated by mTORC1. Ras-homolog enriched in brain (Rheb) is a small GTPase that activates mTORC1 (Inoki et al., 2003; Tee et al., 2003) . Tuberous sclerosis complex (TSC1/2) acts as a GAP toward Rheb, thereby suppressing mTORC1 signaling (Laplante and Sabatini, 2012) . We used TSC2 knockout (KO) MEFs (Zhang et al., 2003) to determine the effects of mTORC1 hyperactivation on mitochondrial biogenesis and functions. As expected, TSC2 KO MEFs exhibited elevated phosphorylation of 4E-BP1 and S6K1 as compared to wild-type (WT) cells ( Figure 5A ). Moreover, levels of ATP5D and TFAM proteins were also higher in TSC2 KO than in WT MEFs ( Figure 5A ).
Cell Metabolism mTORC1/4E-BP Controls Mitochondrial Function
As reported previously, the proportion of ribosomes engaged in polysomes was higher in TSC2 KO as compared to WT MEFs ( Figure 5B ) (Conn and Qian, 2013; Sun et al., 2011) . Importantly, ATP5D and TFAM but not b-actin mRNAs were shifted toward heavy polysome fractions in TSC2 KO as compared to WT MEFs, indicating that loss of TSC2 selectively bolsters translation of ATP5D and TFAM mRNAs ( Figure 5C ). Consistent with previous findings (Cunningham et al., 2007; Schieke et al., 2006) , loss of TSC2 expression increased mitochondrial respiration, mitochondrial DNA content, and ATP levels ( Figures 5D-5F ). These results further support the conclusion that mTORC1 modulates mitochondrial activity and biogenesis by stimulating translation of a subset of mitochondria-related mRNAs.
4E-BPs Are Mediators of mTORC1-Dependent Control of Mitochondrial Function
4E-BPs are implicated in the regulation of mitochondrial function in Drosophila and mammals (Goo et al., 2012; Zid et al., 2009 ). Therefore, we investigated the role of 4E-BPs in mediating the effects of asTORi on translation of mitochondria-related mRNAs. To this end, we depleted 4E-BP1 and 4E-BP2 (4E-BP1/2) from MCF7 cells. asTORi impaired global mRNA translation to a higher extent in control versus 4E-BP1/2-depleted cells, as illustrated by a stronger increase in the 80S monosome peak and a decrease in polysomes ( Figure 6A ). Whereas 4E-BP1/2 depletion did not affect polysome distribution of b-actin mRNA ( Figure 6B,  upper) , it prevented the Ink1341-induced shift of TFAM and ATP5O mRNAs toward lighter polysomes ( Figure 6B, lower) . Therefore, 4E-BPs act as major mediators of mTORC1 on translation of TFAM and ATP5O mRNAs. Accordingly, asTORi decreased ATP5O and TFAM protein levels in control, but not in 4E-BP1/2-depleted cells ( Figure 6C ).
We next studied the effects of 4E-BPs on mitochondrial respiration. Although depletion of 4E-BPs did not affect mitochondrial respiration in untreated MCF7 cells ( Figure S3A) , it significantly relieved asTORi-induced inhibition of this process as compared to a control ( Figure 6D ). Parallel results were obtained with 4E-BP1 and 4E-BP2 double knockout (4E-BP DKO) MEFs ( Figures S3B and S3C) . To investigate the impact of 4E-BP1/2 depletion on mTORC1-dependent regulation of TCA cycle, we performed glucose flux analyses ( Figures 6E  and S3D ). In control cells, Ink1341 diminished the proportion of 13 C-labeled TCA cycle intermediates, which was accompanied by an increment of unlabeled metabolites ( Figure 6E) . In contrast, carbon flux of TCA cycle intermediates in 4E-BP1/2-depleted cells was partially resistant to Ink1341 as compared to control cells ( Figure 6E ). Ink1341 also reduced carbon flux from glucose to pyruvate and lactate in control cells, but less so in 4E-BP1/2depleted cells ( Figure S3D ). Finally, depletion of 4E-BPs mitigated the effects of asTORi on mitochondrial DNA content, mitochondrial mass, and intracellular ATP levels ( Figures 6F-6H) . These findings show that the inhibition of mitochondrial activity and biogenesis by asTORi is predominantly mediated by 4E-BPs.
S6Ks, PGC-1a, and HIF-1a Are Not Major Mediators of the Effects of Short-Term mTOR Inhibition on Mitochondria
In addition to 4E-BPs, S6Ks also mediate the effects of mTORC1 on translation (Roux and Topisirovic, 2012) . Using S6K1/2 dou-ble knockout (S6K DKO) MEFs and S6K DKO MEFs in which expression of S6K1 and 2 was reconstituted ( Figure S4A ) (Dowling et al., 2010) , we show that neither under basal conditions nor in response to asTORi treatment do S6Ks affect mitochondrial respiration and glucose flux to pyruvate and lactate ( Figures S4B-S4E ). However, loss of S6K expression resulted in decreased glucose flux to citrate under basal conditions (Figure S4F) and attenuated inhibitory effects of asTORi on citrate production ( Figure S4H) . Citrate metabolism plays a key role in fatty acid synthesis, and it has been reported that S6Ks are major mediators of mTOR function in lipogenesis (Dü vel et al., 2010) . Therefore, it is likely that S6Ks modulate citrate production downstream of mTORC1 in conjunction with their role in lipid synthesis. Nonetheless, these results demonstrate that S6Ks are not major mediators of mTORC1 function in mitochondrial biogenesis and activity.
Although PGC-1a deficiency ( Figure S5A ) impaired mitochondrial respiration ( Figure S5B ), asTORi inhibited this process to a similar extent in WT and PGC-1a KO MEFs ( Figure S5C ). HIF-1a deficiency did not affect basal mitochondrial respiration (Figure S5E) or influence the effects of asTORi on mitochondrial respiration and glucose flux ( Figures S5F and S5G) . Therefore, PGC-1a and HIF-1a do not appear to be required for the suppression of mitochondrial function that is observed after 12 hr of mTOR inhibition.
4E-BPs and Autophagy Independently Mediate the
Effects of asTORi on Mitochondria mTORC1 inhibition activates autophagy, which is a major pathway of degradation of mitochondria (Fleming et al., 2011) . To investigate the possible role of autophagy in mediating the effects of asTORi treatment on mitochondria, we generated WT and 4E-BP DKO MEFs in which autophagy was impaired by ATG5 depletion ( Figure S6A ). As expected, asTORi induced autophagy in control cells as illustrated by a reduction in LC3A-I and concomitant increase in LC3A-II, but not in ATG5depleted cells ( Figure S6A ). ATG5 reduction partially relieved the effects of asTORi on mitochondrial DNA content and mass in WT MEFs (Figures S6B-S6D) . Strikingly, ATG5 depletion in 4E-BP DKO MEFs rescued the reduction caused by asTORi on mitochondrial DNA content and mass ( Figures S6B-S6D) . These findings indicate that translational regulation through 4E-BPs and autophagy collaboratively mediate the effects of mTORC1 on mitochondria.
Re-expression of TFAM Attenuates the Effects of asTORi on Mitochondrial DNA Synthesis TFAM promotes mitochondrial biogenesis by stimulating mitochondrial DNA replication and transcription (Bonawitz et al., 2006) . To determine whether suppression of TFAM translation underlies the effects of the mTORC1/4E-BP pathway on mitochondrial biogenesis, we used a TFAM cDNA lacking its 5 0 UTR whose expression is resistant to asTORi treatment (Figure S7A) . Consistent with previous findings (Bonawitz et al., 2006) , TFAM overexpression increased basal mitochondrial DNA content ( Figure S7B ). More importantly, TFAM overexpression attenuated the effects of Ink1341 on mitochondrial DNA content ( Figure S7C) . These data indicate that suppression of TFAM expression at the level of translation plays a major role mTORC1 Controls Mitochondrial Respiration through 4E-BP Inhibition In Vivo mTORC1 signaling controls oxygen consumption in mice (Polak et al., 2008; She et al., 2007) . To investigate the effects of asTORi on in vivo respiration, WT and 4E-BP DKO mice were treated daily with Ink1341 for 2 weeks. Ink1341 inhibited 23% oxygen consumption in WT, but not in 4E-BP DKO mice ( Figure 7A ). Consistent with a recent finding that a tissuespecific raptor knockout mouse exhibits decreased locomotor activity (Bentzinger et al., 2008; Polak et al., 2008) , Ink1341 suppressed locomotor activity in WT mice, whereas this (D) Model of translational control of mitochondrial function: mTORC1 prevents 4E-BPs from binding to eIF4E and promotes translation of mRNAs encoding mitochondria-related proteins, thereby bolstering mitochondrial energy production. This increase in mitochondrial ATP production fuels mRNA translation, which is one of the most energy consuming processes in the cell. Energy balance between consumption and production is therefore maintained via the mTORC1/4E-BP pathway.
effect was absent in 4E-BP DKO mice ( Figure 7B ). Also, Ink1341 suppressed heat production in WT, but not in 4E-BP DKO mice ( Figure 7C ). Thus, consistent with the in vitro findings, mTORC1 controls mitochondrial respiration and energy metabolism through 4E-BPs in vivo.
DISCUSSION
In this study we describe a feed-forward mechanism whereby translation of nucleus-encoded mitochondria-related mRNAs is modulated via the mTORC1/4E-BP pathway to induce mitochondrial ATP production capacity and thus provide sufficient energy for protein synthesis ( Figure 7D ).
Hyperactivation of mTOR signaling is frequently observed in cancer (Laplante and Sabatini, 2012) , and eIF4E overexpression is tumorigenic in vitro and in vivo (Avdulov et al., 2004; Lazaris-Karatzas et al., 1990; Ruggero et al., 2004; Wendel et al., (D) Total mitochondrial respiration, ATP turnover, proton leak, and coupled/uncoupled respiration rate of cells described in (A) and treated with asTORi for 12 hr were determined using a Clark-type electrode. (E) Mass isotopomers distribution analysis of citrate, isocitrate, and a-ketoglutarate in cells described in (A) and treated with asTORi for 12 hr. Cells were incubated with D[U-13 C]glucose, and isotopomers with the indicated mass shift were analyzed by GC-MS. (F) Relative mitochondrial DNA content from cells described in (A) and treated with asTORi for 24 hr was determined by qPCR. Mitochondrial DNA content was normalized to genomic DNA content. (G) Mitochondrial mass in cells described in (A) treated with asTORi for 24 hr was estimated by monitoring mean fluorescence intensity of MitoTracker by flow cytometry. (H) Quantification of cellular ATP levels in the cells described in (E). Data represent mean ± SD of three independent experiments. For (E), a representative experiment of three independent experiments (each carried out in triplicate) is presented. *p < 0.05. **p < 0.01. See also Figures S3, S4, S5, S6 , and S7.
Cell Metabolism mTORC1/4E-BP Controls Mitochondrial Function 2004). Although altered glucose metabolism (i.e., Warburg effect) is a hallmark of cancer cells (Vander Heiden et al., 2009) , these cells also rely on mitochondrial intermediates to generate building blocks (e.g., nucleic acids and phospholipids) necessary for neoplastic growth (Ward and Thompson, 2012) . The mTORC1/4E-BP pathway promotes ATP production capacity by mitochondria, as well as cell cycle progression (Dowling et al., 2010) . Thus, mTORC1 drives cell proliferation and neoplastic growth by simultaneously activating translation of mRNAs that encode proteins involved in cellular energy production and cell cycle progression.
Notably, in spite of the reduced ATP utilization caused by the inhibition of protein synthesis, an increase in cellular ATP concentration was not observed after mTOR inhibition ( Figure 3J ), which can be explained by the concomitant reduction in mitochondrial respiration ( Figure 3B ). Indeed, asTORi-induced impairment in ATP production is accompanied by reduction in ATP consumption, which results in a state of metabolic quiescence. These data suggest that asTORi may induce a state of ''metabolic dormancy'' in cancer cells, which would predict a cytostatic rather than cytotoxic effect of asTORi in the clinic (Benjamin et al., 2011) .
mTOR is a multifaceted kinase that employs a number of effectors to exert its biological functions (Laplante and Sabatini, 2012) . Accordingly, 4E-BPs affect TCA cycle in conjunction with other mTORC1 targets (e.g., S6Ks; Figures S4F and S4H) and mTORC2 ( Figure 4F ) that have been previously reported to modulate lipogenesis and glycolysis (Dü vel et al., 2010; Hagiwara et al., 2012; Yuan et al., 2012) . However, our results demonstrate that 4E-BPs act as major mediators of the effects of mTORC1 on mitochondrial biogenesis and function. In addition to stimulation of mitochondrial biogenesis by antagonizing 4E-BP-dependent translational repression of mitochondria related mRNAs, mTORC1 inhibits mitochondrial degradation by suppressing autophagy (Figures S6B-S6D ). These findings suggest coordination of translational and autophagy programs that underpin important biological effects of mTORC1 signaling. mTORC1 also stimulates mitochondrial respiration and biogenesis via the transcriptional regulators PGC-1a and HIF-1a (Cunningham et al., 2007; Dü vel et al., 2010) . However, neither PGC-1a nor HIF-1a appeared to impair mitochondrial activity after 12 hr inhibition of mTOR ( Figure S5 ). Accordingly, we did not observe major changes in mRNA steady-state levels of a subset of mitochondria-related genes as a consequence of mTOR inhibition ( Figure 1C ). It is well established that the changes in gene expression that occur at the level of transcription are heralded by those that take place at the posttranscriptional level (Anderson, 2010) . Therefore, it is likely that mTORC1-dependent changes in translation of mitochondriarelated mRNAs precede transcriptional regulation. PGC-1a-dependent transcriptional change of mitochondria-related genes was observed in myoblasts in which mTORC1 was inhibited for at least 16 hr (Blä ttler et al., 2012) . Moreover, mitochondria-related genes whose expression is regulated by mTORC1 at the level of translation (ATP5O and ATP5D) were not identified as transcriptional targets of mTORC1 (Cunningham et al., 2007) . Hence, it is conceivable that mTOR drives mitochondrial function by simultaneously orchestrating translational and transcriptional programs to modulate expression of mitochondria-related genes.
Two recent studies suggested that the inhibition of mTORC1 by asTORi suppresses 5 0 TOP mRNA translation in a 4E-BPdependent manner (Hsieh et al., 2012; Thoreen et al., 2012) . Herein, using a battery of well-established biochemical and functional assays, we demonstrate that the mTORC1/4E-BP pathway stimulates mitochondrial functions by enhancing the translation of a subset of mitochondria-related mRNAs, which largely do not harbor 5 0 TOP elements.
In summary, we demonstrate that the mTORC1/4E-BP pathway controls cellular energy homeostasis via translation of nucleus-encoded mitochondria-related genes. This uncovers an important mechanism that explains the role of mTOR signaling in diseases characterized by metabolic perturbations, such as cancer.
EXPERIMENTAL PROCEDURES

Genome-wide Analysis of mRNA Translation Following Treatment with PP242
We used data sets containing steady-state and polysome-associated mRNA obtained from MCF7 cells treated with vehicle or PP242 for 12 hr from our previous study that were deposited at the Gene Expression Omnibus (GEO, GSE36847) (Larsson et al., 2012) . Differential translation was calculated using anota analysis (Larsson et al., , 2011 , which corrects changes in polysome-associated mRNA for changes in cytoplasmic steady-state mRNA. We used GAGE (Luo et al., 2009) to identify cellular processes (as defined by the Gene Ontology Consortium) showing a significant gene set enrichment among genes that were translationally suppressed (using data from the anota analysis) following treatment with PP242. We applied the ''rank.test'' option in GAGE using signed (direction of regulation) Àlog10(FDR) as input data within the ''gage'' bioconductor package (Gentleman et al., 2004) . Cellular processes that showed an enrichment in FDR < 0.05 and were related to mitochondrial function were selected (shown in Figure 1A ). We also compared fold changes (PP242 treatment versus control) in steady-state mRNA levels and translation activity (i.e., obtained by anota analysis) for the subset of mitochondrial genes that were identified as differentially regulated at the level of translation following treatment with PP242. Kernel densities for the observed fold changes (PP242 versus vehicle treatment) were obtained using the ''density'' function in ''R'' (http://www.r-project.org) with default settings and presented in Figure 1C .
Cell Culture, Lentivirus shRNA Silencing, and mTOR Inhibitors Cell culture and lentivirus shRNA silencing were carried out as described (Dowling et al., 2010) . The information about all MEFs is described in Supplemental Experimental Procedures. For lentivirus production, lentiviral vectors were cotransfected into HEK293T cells with the lentivirus packaging plasmids PLP1, PLP2, and PLP-VSVG (Invitrogen) using Lipofectamine (Invitrogen). Supernatants were collected 48 and 72 hr postinfection, passed through a 0.45 mm nitrocellulose filter, and applied on target cells with polybrene (1 mg/ml). Cells were reinfected the next day and selected with puromycin (5 mg/ml) for 48 hr. The information about lentiviral vectors is described in Supplemental Experimental Procedures. PP242 and Ink1341 were provided by Intellikine, and Torin1 was obtained from Tocris Bioscience. For all experiments, cells were seeded at $50% confluency, grown overnight, and treated with vehicle (DMSO), PP242 (2.5 mM), Ink1341 (250 nM), or Torin1 (250 nM).
Polysome Profiling, RNA Isolation and RT-sqPCR
Polysome profiling and RT-sqPCR were carried out as described (Dowling et al., 2010) . Briefly, cells were cultured in 15 cm dishes, treated with the indicated drugs or vehicle for 12 hr, washed twice with cold PBS containing 100 mg/ml cycloheximide, collected, and lysed in 450 ml of hypotonic buffer (5 mM Tris-HCl [pH 7.5], 2.5 mM MgCl 2 , 1.5 mM KCl, 100 mg/ml cycloheximide, 2 mM DTT, 0.5% Triton X-100, and 0.5% sodium deoxycholate). Lysates were loaded onto 10%-50% (wt/vol) sucrose density gradients (20 mM HEPES-KOH [pH 7.6], 100 mM KCl, and 5 mM MgCl 2 ) and centrifuged at 36,000 rpm (SW 40 Ti rotor, Beckman Coulter, Inc.) for 2 hr at 4 C. Gradients were fractionated and optical density at 254 nm was continuously recorded using an ISCO fractionator (Teledyne ISCO). RNA from each fraction and input was isolated using TRIzol (Invitrogen) according to the manufacturer's instructions. RT-sqPCR reactions were carried out using SuperScript III First-Strand Synthesis System (Invitrogen) and iQ SYBR Green Supermix (Bio-Rad) according to the manufacturers' instructions. The list of primers is provided in Table S3 .
Cell Lysis, Western Blotting, and Cap (m 7 GDP) Pull-Down Assay Cells were lysed in lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1% NP-40, Roche complete protease inhibitor cocktail). Protein concentrations were estimated with the Bio-Rad protein assay, and western blotting was carried out as described (Dowling et al., 2010) . The information about antibodies is described in Supplemental Experimental Procedures. Cap pull-down assay was carried out as described (Dowling et al., 2010) . Briefly, cells were lysed by three freeze-thaw cycles in the cap pull-down buffer (50 mM HEPES-KOH [pH 7.5], 150 mM KCl, 1 mM EDTA, 2 mM DTT, and 0.2% Tween-20) containing protease inhibitors. Protein extract (1 mg) was incubated for 2 hr at 4 C with m 7 GDP-agarose beads. After incubation, beads were washed five times with the cap pull-down buffer and eluted by boiling in the presence of 13 sample buffer for 5 min. m 7 GDP-bound proteins were visualized by western blotting.
Respiration Assay
The respiration assay was carried out as described (Eichner et al., 2010) . Briefly, cells were cultured in 10 cm or 15 cm dishes, treated with the indicated drugs or vehicle for 12 hr, trypsinized, and resuspended in PBS supplemented with 25 mM glucose, 1 mM pyruvate, and 2% BSA. A TC10 automated cell counter assessed total cell count and cell viability via Trypan blue dye exclusion (Bio-Rad). A total of 2.0 3 10 6 cells were placed in the chamber of a Clark-type oxygen electrode, and cellular respiration was measured. Oligomycin-sensitive respiration represents ATP turnover. Oligomycin-insensitive respiration represents proton leak. Myxothiazol was added to quantify nonmitochondrial respiration. In all experiments performed, nonmitochondrial respiration was undetectable.
Mitochondrial DNA Quantification and Mitochondrial Mass Quantification
The mitochondrial DNA quantification assay was carried out as described (Cunningham et al., 2007) . Briefly, cells were treated with the indicated drugs or vehicle for 24 hr. Genomic and mitochondrial DNA was extracted using DNeasy Blood and Tissue kit (QIAGEN). Genomic and mitochondrial DNA was quantified by qPCR using iQ SYBR Green Supermix (Bio-Rad). The list of primers is provided in Table S3 .
For the quantification of mitochondrial mass, drug-treated cells were trypsinized, washed with PBS twice, and stained with 10% FBS-DMEM containing 500 nM MitoTracker Deep Red FM (Invitrogen) for 30 min at 37 C. MitoTracker fluorescence intensities were analyzed by FACS (BD). Relative mean fluorescence intensities were calculated by FlowJo (Tree Star, Inc.) and used to determine mitochondrial mass.
LC-MS, NMR, and Mass Isotopomer Distribution Analysis by GC-MS
LC-MS and NMR analyses and mass isotopomer distribution analysis are described in Supplemental Experimental Procedures. Briefly, for LC-MS and NMR analyses, cells were treated with vehicle or asTORi for 12 hr, and metabolites were extracted and analyzed by LC-MS or NMR. For mass isotopomer distribution analysis, cell were treated with vehicle or asTORi for 12 hr and washed with PBS, and media containing 10% dialyzed FBS and 5.55 mM D [U-13 C]glucose (Cambridge Isotope Laboratories) was added for 30 min. Cells were washed with ice-cold normal saline solution, and metabolites were extracted and analyzed by GC-MS.
In Vivo Metabolic Studies
In vivo metabolic studies are described in Supplemental Experimental Procedures. Briefly, each mouse was housed in a separate cage and maintained on a 12 hr dark-light cycle with access to food and water ad libitum. For asTORi treatment, Ink1341 was formulated in 5% NMP (1-methyl-2-pyrrolidinone), 15% polyvinylpyrrolidone K30, and 80% water and administrated intraperitoneally at 3 mg/kg body weight daily for 2 weeks. Oxygen consumption, locomotor activity, and heat production were determined with an Oxymax-CLAMS system (Columbus Instruments) according to the manufacturer's instruction. All mouse experiments were carried out in accordance with the guidelines for animal use issued by the McGill University Animal Care Committee.
Statistical Analysis
All values represent mean ± standard deviation (SD) of three independent experiments (unless otherwise indicated). Differences between groups were examined for statistical significance using Student's t test (two-tailed distribution with two-sample equal variance). We considered a p value of < 0.05 statistically significant.
SUPPLEMENTAL INFORMATION
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